AstraZeneca Re-Confirms Forecast Following Goof (AZN)
January 9, 2012 by Paul AusickDrug maker AstraZeneca PLC (NYSE: AZN) has issued a press release re-confirming the company’s December forecast following a load of bad data sent to analysts:
During a routine consensus collection process, confidential Company information was inadvertently embedded in a spreadsheet template sent to the sell-side analyst community that follows the Company. This information is out of date planning information, and does not represent the Company’s view of expected financial performance for the full year 2011 or for future periods.
The company reiterated that it expects earnings for the full 2011 fiscal year to be in the lower half of a range of $7.20-$7.40. AstraZeneca also said that its previously planning assumptions are unchanged.
Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.